Atheir Abbas1, Bryan L Roth. 1. Case Western Reserve University School of Medicine, Biochemistry, Cleveland, OH 44106, USA. aia4@case.edu
Abstract
BACKGROUND: Pimavanserin tartrate is the first 5-HT(2A) inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. Pimavanserin is also being evaluated as a possible anti-insomnia drug. OBJECTIVE: To discuss the potential of pimavanserin to fill multiple therapeutic needs. METHODS: The problems with currently approved antipsychotics and sleep agents are explored to highlight how pimavanserin might address some longstanding issues in the treatment of psychosis and insomnia. RESULTS/ CONCLUSIONS: In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L-dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals.
BACKGROUND:Pimavanserin tartrate is the first 5-HT(2A) inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. Pimavanserin is also being evaluated as a possible anti-insomnia drug. OBJECTIVE: To discuss the potential of pimavanserin to fill multiple therapeutic needs. METHODS: The problems with currently approved antipsychotics and sleep agents are explored to highlight how pimavanserin might address some longstanding issues in the treatment of psychosis and insomnia. RESULTS/ CONCLUSIONS: In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L-dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals.
Authors: Jelveh Lameh; Krista McFarland; Jorgen Ohlsson; Fredrik Ek; Fabrice Piu; Ethan S Burstein; Ali Tabatabaei; Roger Olsson; Stefania Risso Bradley; Douglas W Bonhaus Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2011-11-15 Impact factor: 3.000
Authors: Justin L Poklis; Carol R Nanco; Michelle M Troendle; Carl E Wolf; Alphonse Poklis Journal: Drug Test Anal Date: 2013-09-02 Impact factor: 3.345
Authors: Justin L Poklis; Kelly G Devers; Elise F Arbefeville; Julia M Pearson; Eric Houston; Alphonse Poklis Journal: Forensic Sci Int Date: 2013-10-18 Impact factor: 2.395